Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm. Cytoplasm, perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, cilium basal body Note=Detected at the microtubule cytoskeleton during interphase. Detected at the midbody during telophase. During metaphase, it remains localized to the centrosome but is also present along the spindle (PubMed:25134987). |
Domain |
PF01302 CAP-Gly domain PF00443 Ubiquitin carboxyl-terminal hydrolase |
Function |
Deubiquitinase that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Also able to remove linear ('Met-1'-linked) polyubiquitin chains to regulate innate immunity: recruited to the LUBAC complex and, together with OTULIN, restricts linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26670046, PubMed:26997266). |
Biological Process |
GO:0000226 microtubule cytoskeleton organization GO:0001818 negative regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002753 cytoplasmic pattern recognition receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0006606 protein import into nucleus GO:0006913 nucleocytoplasmic transport GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007346 regulation of mitotic cell cycle GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway GO:0010927 cellular component assembly involved in morphogenesis GO:0016055 Wnt signaling pathway GO:0016579 protein deubiquitination GO:0017038 protein import GO:0022604 regulation of cell morphogenesis GO:0030031 cell projection assembly GO:0030111 regulation of Wnt signaling pathway GO:0030178 negative regulation of Wnt signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0031349 positive regulation of defense response GO:0031503 protein complex localization GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032479 regulation of type I interferon production GO:0032480 negative regulation of type I interferon production GO:0032606 type I interferon production GO:0032886 regulation of microtubule-based process GO:0033157 regulation of intracellular protein transport GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0034504 protein localization to nucleus GO:0034612 response to tumor necrosis factor GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway GO:0042306 regulation of protein import into nucleus GO:0042308 negative regulation of protein import into nucleus GO:0042345 regulation of NF-kappaB import into nucleus GO:0042347 negative regulation of NF-kappaB import into nucleus GO:0042348 NF-kappaB import into nucleus GO:0042384 cilium assembly GO:0042990 regulation of transcription factor import into nucleus GO:0042991 transcription factor import into nucleus GO:0042992 negative regulation of transcription factor import into nucleus GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0044744 protein targeting to nucleus GO:0044782 cilium organization GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0046822 regulation of nucleocytoplasmic transport GO:0046823 negative regulation of nucleocytoplasmic transport GO:0051051 negative regulation of transport GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051224 negative regulation of protein transport GO:0051493 regulation of cytoskeleton organization GO:0060070 canonical Wnt signaling pathway GO:0060271 cilium morphogenesis GO:0060491 regulation of cell projection assembly GO:0060759 regulation of response to cytokine stimulus GO:0060828 regulation of canonical Wnt signaling pathway GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway GO:0070507 regulation of microtubule cytoskeleton organization GO:0070536 protein K63-linked deubiquitination GO:0070646 protein modification by small protein removal GO:0071356 cellular response to tumor necrosis factor GO:0090090 negative regulation of canonical Wnt signaling pathway GO:0090317 negative regulation of intracellular protein transport GO:0097191 extrinsic apoptotic signaling pathway GO:0097193 intrinsic apoptotic signaling pathway GO:0097300 programmed necrotic cell death GO:0198738 cell-cell signaling by wnt GO:1900180 regulation of protein localization to nucleus GO:1900181 negative regulation of protein localization to nucleus GO:1902017 regulation of cilium assembly GO:1902115 regulation of organelle assembly GO:1902532 negative regulation of intracellular signal transduction GO:1902593 single-organism nuclear import GO:1903533 regulation of protein targeting GO:1903828 negative regulation of cellular protein localization GO:1904589 regulation of protein import GO:1904590 negative regulation of protein import GO:1904950 negative regulation of establishment of protein localization GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001238 positive regulation of extrinsic apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway |
Molecular Function |
GO:0004843 thiol-dependent ubiquitin-specific protease activity GO:0008234 cysteine-type peptidase activity GO:0019783 ubiquitin-like protein-specific protease activity GO:0036459 thiol-dependent ubiquitinyl hydrolase activity GO:0061578 Lys63-specific deubiquitinase activity GO:0070064 proline-rich region binding GO:0101005 ubiquitinyl hydrolase activity |
Cellular Component |
GO:0005813 centrosome GO:0005819 spindle GO:0005874 microtubule GO:0005881 cytoplasmic microtubule GO:0005929 cilium GO:0009898 cytoplasmic side of plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0030496 midbody GO:0031234 extrinsic component of cytoplasmic side of plasma membrane GO:0036064 ciliary basal body GO:0044441 ciliary part GO:0097542 ciliary tip GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane |
KEGG |
hsa04380 Osteoclast differentiation hsa04622 RIG-I-like receptor signaling pathway |
Reactome |
R-HSA-73887: Death Receptor Signalling R-HSA-5688426: Deubiquitination R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-168638: NOD1/2 Signaling Pathway R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways R-HSA-597592: Post-translational protein modification R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-5357905: Regulation of TNFR1 signaling R-HSA-162582: Signal Transduction R-HSA-75893: TNF signaling R-HSA-5357956: TNFR1-induced NFkappaB signaling pathway R-HSA-5357786: TNFR1-induced proapoptotic signaling R-HSA-5689880: Ub-specific processing proteases |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CYLD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CYLD and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CYLD in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CYLD in various data sets.
|
Points in the above scatter plot represent the mutation difference of CYLD in various data sets.
|
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYLD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYLD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYLD. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYLD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CYLD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CYLD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CYLD |
Name | cylindromatosis (turban tumor syndrome) |
Aliases | KIAA0849; USPL2; ubiquitin specific peptidase like 2; CYLD1; BRSS; CDMT1; CYLDI; EAC; MFT1; SBS; deubiquitin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CYLD collected from DrugBank database. |
There is no record. |